NCT02398669

A Single Dose Pharmacokinetic Study of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of Age

An Open-Label, Single Dose Study to Assess Pharmacokinetics, Safety and Tolerability of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of Age

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Eisai Inc. · Industry
• Sex: All
• Age: 6 Years – 11 Years
• Healthy volunteers: Not accepted

Summary

Study will evaluate the pharmacokinetics (PK), safety and tolerability of a single 10 mg dose of lorcaserin hydrochloride in obese pediatric subjects 6 to 11 years of age.

Conditions

• Obesity

Interventions

Type	Name	Description
DRUG	Lorcaserin hydrochloride	A single 10 mg dose of oral tablet formulation of lorcaserin hydrochloride will be administered with 240 mL of water.

Timeline

• Start date: 2015-03-01
• Primary completion: 2015-04-01
• Completion: 2015-05-01
• First posted: 2015-03-25
• Last updated: 2015-11-03

Locations

1 site across 1 country: United States